<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431350</url>
  </required_header>
  <id_info>
    <org_study_id>CR108406</org_study_id>
    <secondary_id>64091742PCR2002</secondary_id>
    <secondary_id>2017-003552-23</secondary_id>
    <nct_id>NCT03431350</nct_id>
  </id_info>
  <brief_title>A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <acronym>QUEST</acronym>
  <official_title>A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to&#xD;
      evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1&#xD;
      and 2) and b) to determine the relative bioavailability of niraparib and abiraterone acetate&#xD;
      (AA) in combination (Combination 3) in participants with metastatic castration-resistant&#xD;
      prostate cancer (mCRPC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter study will evaluate safety and efficacy of niraparib in combination with&#xD;
      other anti-cancer agents. Combination 1 will combine niraparib with the anti-programmed cell&#xD;
      death protein (PD)-1 monoclonal antibody cetrelimab, in participants with mCRPC. Combination&#xD;
      1 has 2 parts: in Part 1 (dose selection), participants will be enrolled to establish RP2D&#xD;
      doses of niraparib and cetrelimab; and Part 2 (dose expansion) will evaluate the combination&#xD;
      therapy in an expanded number of participants into 2 cohorts (biomarker positive or biomarker&#xD;
      negative). Combination 2 will combine niraparib with abiraterone acetate plus prednisone&#xD;
      (AA-P) in mCRPC participants with DNA-repair gene defects (DRD). Combination 3 will evaluate&#xD;
      the relative bioavailability (BA) of niraparib and AA in combination. In a pharmacokinetics&#xD;
      (PK) assessment phase, niraparib and AA will be administered, and in an extension phase,&#xD;
      niraparib and AA-P will be administered. Combinations 1 and 2 will have 5 phases: A&#xD;
      Pre-screening Phase, a Screening Phase, a Treatment Phase, a Follow-up Phase, and a Long-term&#xD;
      Extension (LTE) Phase; Combination 3 has 3 phases: A Screening Phase, A PK Assessment Phase,&#xD;
      an Extension Phase (including LTE phase). Study evaluations will include efficacy, PK,&#xD;
      PK/pharmacodynamics, biomarkers, safety and tolerability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Combination 1: Incidence of Specified Toxicities</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Incidence defined as number of participants with specified toxicities will be reported. The dose will be considered intolerable if a participant developed Grade greater than or equal to (&gt;=) 3 non-hematological toxicity (with exceptions including anorexia, fever, constipation, fatigue that improves to Grade less than or equal to (&lt;=) 2 in &lt;=7 days, vomiting and diarrhea that resolves in &lt;=3 days with best supportive care), treatment-related Grade 4 thrombocytopenia or Grade &gt;= 3 thrombocytopenia, treatment-related Grade 4 neutropenia &gt;= 7 days, or Grade 3 or 4 neutropenia, treatment-related serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Combination 1: Objective Response Rate (ORR)</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Objective response rate is defined as the percentage of participants who achieve complete response (CR) or partial response (PR), as assessed by response evaluation criteria in solid tumors (RECIST) 1.1 criteria with no evidence of bone progression according to prostate cancer working group 3 (PCWG3) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Combinations 1: Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Incidence defined as number of participants with AEs will be reported. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Combinations 1: Severity of Adverse Events</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Any AE not listed in the NCI-CTCAE will be graded according to the investigator's clinical judgment using the standard grades.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Combination 2: Composite Response Rate (RR)</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Composite response rate (RR) is defined as percentage of participants who have 1 of the following by PCWG3 criteria: Objective response (confirmed per RECIST 1.1), or circulating tumor cells (CTC) response: defined as CTC=0 per 7.5 milliliter (mL) of blood at 8 weeks for participants who have CTC greater than or equal to (&gt;=)1 at baseline or CTC less than (&lt;)5 per 7.5 mL with CTC &gt;=5 at baseline, confirmed by a second consecutive value obtained 4 or more weeks later, or prostate-specific antigen (PSA) decline of &gt;=50%, measured twice 3 to 4 weeks apart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combination 3: Maximum Observed Analyte Plasma Concentration (Cmax) of Niraparib and AA After a Single Dose</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
    <description>Cmax is defined as the maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combination 3: Maximum Observed Analyte Plasma Concentration for Niraparib Normalized by the Dose (Cmax/dose) of Niraparib and AA After a Single Dose</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
    <description>Cmax/dose is defined as maximum observed analyte plasma concentration for niraparib normalized by the dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combination 3: Area Under the Plasma Concentration-Time Curve from Time Zero to 168 Hours (AUC [0-168]) of Niraparib and AA After a Single Dose</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
    <description>AUC (0-168) is defined as area under plasma concentration-time curve from time 0 to time 168 hours post dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combination 3: Area Under the Plasma Concentration-Time Curve for Niraparib from Time Zero to 168 Hours (AUC [0-168]/dose) of Niraparib and AA After a Single Dose</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
    <description>AUC (0-168)/dose is defined as area under plasma concentration-time curve for niraparib from time 0 to time 168 hours post dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Combination 1: Number of Participants with Circulating Tumor Cell (CTC) Response</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>CTC response is defined as CTC=0 per 7.5 milliliter (mL) of blood at 8 weeks for participants who have CTC &gt;= 1 at baseline or CTC&lt;5 per 7.5 mL with CTC &gt;=5 at baseline, confirmed by a second consecutive value obtained 4 or more weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Combination 1: Composite Response Rate (RR)</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Composite RR is defined as percentage of participants who have 1 of the following by PCWG3: Objective response (confirmed per RECIST 1.1), or CTC response: defined as CTC=0 per 7.5 mL of blood at 8 weeks for participants who have CTC &gt;=1 at baseline or CTC &lt;5 baseline per 7.5 mL with CTC&gt;5 at baseline, confirmed by a second consecutive value obtained 4 or more weeks later, or PSA decline of &gt;= 50%, measured twice 3 to 4 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Combination 1: Duration of Objective Response</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>Duration of objective response is defined as time from complete response (CR) or partial response (PR) to radiographic progression of disease (PD), unequivocal clinical progression, or death, whichever occurs first. CR defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than 10 millimeter (mm). PR defined as at least 30 % decrease in sum of the diameters of the target lesions taking as reference the baseline sum diameters. PD is defined as a 20% increase in the sum of diameters of all target lesions and a minimum absolute increase of 5 mm in the sum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Combination 1: Overall Survival (OS)</measure>
    <time_frame>Up to 46 months</time_frame>
    <description>OS is defined as time from start of treatment to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Combination 2: Objective Response Rate (ORR)</measure>
    <time_frame>Up to 42 months</time_frame>
    <description>ORR of soft tissue (visceral or nodal disease) as defined by RECIST 1.1 with no evidence of bone progression according to PCWG3 criteria. As per RECIST 1.1 criteria, ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR), as assessed by response evaluation criteria in solid tumors (RECIST) 1.1 criteria with no evidence of bone progression according to prostate cancer working group 3 (PCWG3) criteria. CR defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of the diameters of the target lesions taking as reference the baseline sum diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination 3: Number of Participants with Adverse Events</measure>
    <time_frame>Up to 46 months</time_frame>
    <description>Number of participants with adverse events will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination 3: Number of Participants with Abnormal Clinical Laboratory Findings</measure>
    <time_frame>Up to 46 months</time_frame>
    <description>Number of participants with abnormal clinical laboratory findings (hematology and serum chemistry) will be reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Prostatic Neoplasms, Castration-Resistant</condition>
  <arm_group>
    <arm_group_label>Combination 1:Dose Selection: Niraparib + cetrelimab (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 1: The participants will receive niraparib 200 milligram (mg) orally once daily in combination with cetrelimab 240 mg intravenously (IV) once every 2 weeks. Dose regimen 2: The participants will receive niraparib 200 mg orally once daily in combination with cetrelimab 480 mg IV once every 4 weeks in 28-day treatment cycles until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. The safety evaluation team (SET) will determine if an additional cohort is necessary, based on the data from dose regimens 1 and 2. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination 1:Dose Expansion: Niraparib + cetrelimab (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned to either Cohort 1A (Biomarker [BM] positive [+]) or Cohort 1B (BM negative [-]) and will receive established RP2D of cetrelimab and niraparib, in Part 2 until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. A futility analysis will be performed for the Cohort 1B after 10 BM- participants are enrolled in Part 2. This cohort will be closed if the response is less than predetermined response rate as outlined in the protocol. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination 2: Dose Expansion: Niraparib + AA-P (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned to one of 4 cohorts based on biomarker status - Cohort 2A (BRCA biallelic loss), 2B (other DRD biallelic loss), 2C (BRCA monoallelic loss), or 2D (other DRD monoallelic loss), and will receive niraparib 200 mg once daily in combination with abiraterone acetate 1000 mg (4*250 mg) plus 10 mg prednisone (5 mg twice daily) throughout treatment phase. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination 3: Niraparib + AA-P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned to one of three cohorts to receive AA-P with or without niraparib. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib 200 mg</intervention_name>
    <description>Participants will receive niraparib 200 mg orally.</description>
    <arm_group_label>Combination 1:Dose Expansion: Niraparib + cetrelimab (Part 2)</arm_group_label>
    <arm_group_label>Combination 1:Dose Selection: Niraparib + cetrelimab (Part 1)</arm_group_label>
    <arm_group_label>Combination 2: Dose Expansion: Niraparib + AA-P (Part 2)</arm_group_label>
    <arm_group_label>Combination 3: Niraparib + AA-P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrelimab 240 mg</intervention_name>
    <description>Participants will receive cetrelimab 240 mg IV every 2 weeks.</description>
    <arm_group_label>Combination 1:Dose Selection: Niraparib + cetrelimab (Part 1)</arm_group_label>
    <other_name>JNJ-63723283</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrelimab 480 mg</intervention_name>
    <description>Participants will receive cetrelimab 480 mg IV every 4 weeks.</description>
    <arm_group_label>Combination 1:Dose Expansion: Niraparib + cetrelimab (Part 2)</arm_group_label>
    <arm_group_label>Combination 1:Dose Selection: Niraparib + cetrelimab (Part 1)</arm_group_label>
    <other_name>JNJ-63723283</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate 1000 mg</intervention_name>
    <description>Participants will receive AA 1000 mg orally.</description>
    <arm_group_label>Combination 2: Dose Expansion: Niraparib + AA-P (Part 2)</arm_group_label>
    <arm_group_label>Combination 3: Niraparib + AA-P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone 5 mg</intervention_name>
    <description>Participants will receive prednisone 5 mg orally.</description>
    <arm_group_label>Combination 2: Dose Expansion: Niraparib + AA-P (Part 2)</arm_group_label>
    <arm_group_label>Combination 3: Niraparib + AA-P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Combination 3:&#xD;
&#xD;
          -  Diagnosed with mCRPC, who in the opinion of the investigator may benefit from&#xD;
             treatment in Combination 3 of this study&#xD;
&#xD;
          -  Able to continue gonadotropin releasing hormone analogue (GnRHa) therapy during the&#xD;
             study if not surgically castrate (that is, subjects who has not undergone bilateral&#xD;
             orchiectomy).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of less than or equal&#xD;
             to (&lt;=) 1&#xD;
&#xD;
          -  Toxicity associated with prior chemotherapy or radiotherapy has resolved to Grade &lt;= 1&#xD;
             (except alopecia or Grade &lt;= 2 neuropathy) at screening&#xD;
&#xD;
          -  Participant must agree not to donate sperm while on study treatment, and for 3 months&#xD;
             following the last dose of study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia&#xD;
             (AML)&#xD;
&#xD;
          -  Active malignancies (that is, progressing or requiring treatment change in the last 24&#xD;
             months) other than the disease being treated under study. The only allowed exceptions&#xD;
             are: non-muscle invasive bladder cancer; skin cancer (non-melanoma or melanoma);&#xD;
             breast cancer; malignancy that is considered cured with minimal risk of recurrence&#xD;
&#xD;
          -  Active infection requiring systemic therapy&#xD;
&#xD;
          -  Allergies, hypersensitivity, or intolerance to niraparib or the corresponding&#xD;
             excipients&#xD;
&#xD;
        Combination 3:&#xD;
&#xD;
          -  Symptomatic brain metastases&#xD;
&#xD;
          -  Prior disease progression during combination treatment with AA and poly (adenosine&#xD;
             diphosphate [ADP]-ribose) polymerase inhibitor (PARPi). Prior discontinuation of&#xD;
             treatment with AA or PARPi due to AA- or PARPi-related toxicity&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urological Associates of Southern Arizona, P.C.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Center of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Division Of Hematology/oncology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Urology, PSC</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Institute of Urology</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUSC-Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Metro Urology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia, PLCC</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>5379200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLV Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB HÃ´pital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Alberta Institute of Urology / Prostate Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 1P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network (UHN) Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asaf Harofe Medical Center</name>
      <address>
        <city>Beer Yaakov</city>
        <zip>60930</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Hospital</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>85101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center Tel Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi di Firenze</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera ''Vito Fazzi''</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Ospedale Provinciale di Macerata</name>
      <address>
        <city>Macerata</city>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS-Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Fund. Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Hm Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Virgen de La Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>WC1E 6BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Trust Sutton</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

